Get the Stockscreener App
651.80
0.34%
-2.24
After Hours:
653.00
1.20
+0.18%
Regeneron Pharmaceuticals Inc stock is traded at $651.80, with a volume of 797.91K.
It is down -0.34% in the last 24 hours and up +15.92% over the past month.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
See More
Previous Close:
$654.04
Open:
$649.45
24h Volume:
797.91K
Relative Volume:
0.75
Market Cap:
$67.90B
Revenue:
$14.25B
Net Income/Loss:
$4.58B
P/E Ratio:
15.60
EPS:
41.7701
Net Cash Flow:
$3.88B
1W Performance:
+12.78%
1M Performance:
+15.92%
6M Performance:
+8.86%
1Y Performance:
-22.24%
1-Day Range:
$645.00
$660.00
1-Week Range:
$575.93
$664.00
52-Week Range:
$476.49
$862.00
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Name
Regeneron Pharmaceuticals Inc
Sector
Industry
Phone
(914) 847-7000
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-14-25 | Initiated | Rothschild & Co Redburn | Buy |
| Jun-30-25 | Downgrade | Argus | Buy → Hold |
| May-30-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-14-25 | Upgrade | Citigroup | Neutral → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-05-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jan-16-25 | Downgrade | UBS | Buy → Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Sep-24-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-12-24 | Initiated | Bernstein | Outperform |
| Jan-12-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-03-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-21-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-21-23 | Reiterated | Oppenheimer | Perform |
| Jun-28-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-27-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-24-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-23-23 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jan-30-23 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-20-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-26-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Oct-17-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-09-22 | Upgrade | Jefferies | Underperform → Hold |
| Sep-09-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-25-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-15-21 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Dec-07-21 | Resumed | Cowen | Market Perform |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Resumed | BMO Capital Markets | Outperform |
| Nov-05-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-29-21 | Initiated | H.C. Wainwright | Buy |
| Jan-25-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-13-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-08-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-05-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-20-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-09-20 | Upgrade | SunTrust | Hold → Buy |
| May-26-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-17-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Apr-08-20 | Initiated | The Benchmark Company | Hold |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-26-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-25-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-11-20 | Upgrade | Argus | Hold → Buy |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-16-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-13-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-12-19 | Initiated | SunTrust | Hold |
| Nov-07-19 | Upgrade | Citigroup | Neutral → Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
View All
Regeneron Pharmaceuticals Inc Stock (REGN) Latest News
Antibody Cocktails Market See Incredible Growth 2025-2032 - openPR.com
Using fundamentals and technicals on Regeneron Pharmaceuticals Inc.Market Movement Recap & Long-Term Investment Growth Plans - newser.com
Published on: 2025-11-02 22:34:33 - newser.com
Is Regeneron Pharmaceuticals Inc. stock positioned for digital transformationWeekly Trend Report & Low Risk High Win Rate Stock Picks - newser.com
Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More Than 130% - The Motley Fool
News impact scoring models applied to Regeneron Pharmaceuticals Inc.Quarterly Trade Report & Growth Focused Entry Reports - newser.com
What data driven models say about Regeneron Pharmaceuticals Inc.’s futureMarket Movement Recap & Real-Time Buy Zone Alerts - newser.com
AMG National Trust Bank Buys Shares of 5,969 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Heatmap analysis for Regeneron Pharmaceuticals Inc. and competitorsWeekly Volume Report & Expert Approved Momentum Trade Ideas - newser.com
Atria Investments Inc Purchases 1,442 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Envestnet Asset Management Inc. Decreases Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Arkadios Wealth Advisors Has $1.07 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Oppenheimer Asset Management Inc. Purchases 643 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Will earnings trigger a reversal in Regeneron Pharmaceuticals Inc.2025 Earnings Surprises & Entry Point Strategy Guides - newser.com
Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at Wall Street Zen - MarketBeat
How currency fluctuations impact Regeneron Pharmaceuticals Inc. stockForecast Cut & Technical Pattern Recognition Alerts - newser.com
Pharmaceutical Stocks To Keep An Eye OnOctober 28th - MarketBeat
Christine Poon Sells 6,500 Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) Stock - MarketBeat
Combining price and volume data for Regeneron Pharmaceuticals Inc.Quarterly Portfolio Summary & Community Verified Watchlist Alerts - newser.com
Is Regeneron Pharmaceuticals Inc. trending in predictive chart modelsMarket Performance Recap & Weekly Stock Performance Updates - newser.com
What does recent volatility data suggest for Regeneron Pharmaceuticals Inc.July 2025 Market Mood & Momentum Based Trading Ideas - newser.com
Why Regeneron Pharmaceuticals Inc. (RGO) stock is listed among top recommendationsJuly 2025 Sentiment & Stock Market Timing Techniques - newser.com
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Pinnacle Associates Ltd. - MarketBeat
Amalgamated Bank Sells 557 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Published on: 2025-11-01 03:40:36 - newser.com
Why millennials buy Regeneron Pharmaceuticals Inc. (RGO) stockMarket Trend Report & Free Technical Confirmation Trade Alerts - newser.com
Regeneron Pharmaceuticals, Inc. $REGN Stake Lessened by Brighton Jones LLC - MarketBeat
Regeneron Pharmaceuticals (REGN): Evaluating Valuation as Momentum Builds After Recent Share Price Gains - simplywall.st
Why Regeneron Pharmaceuticals Inc. stock is considered a top pick2025 Market Outlook & AI Driven Stock Movement Reports - newser.com
Is OPKO’s Regeneron Deal and Asset Sale Shifting the Investment Case for OPKO Health (OPK)? - Yahoo Finance
Regeneron, the False Claims Act, and a New Era in Government Enforcement - The National Law Review
Rothschild & Co Redburn Adjusts Price Target on Regeneron Pharmaceuticals to $910 From $900 - MarketScreener
Dupixent wins 2025 Prix Galien USA Best Biotechnology Product award - PharmaLive
UNIVEST FINANCIAL Corp Boosts Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Libtayo® (cemiplimab for injection) Now Reimbursed in Québec for Advanced Non-Small Cell Lung Cancer - BioSpace
Libtayo® (cemiplimab for injection) Now Reimbursed in Seven Provinces for Advanced Non-Small Cell Lung Cancer and Locally Advanced Basal Cell Carcinoma - BioSpace
Retirement Systems of Alabama Has $67.81 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals' Dupixent® Awarded "Best Biotechnology Product" by Galien Foundation for 2025 - Quiver Quantitative
Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award - Caledonian Record
What MACD signals say about Regeneron Pharmaceuticals Inc.Quarterly Earnings Report & Safe Entry Point Alerts - newser.com
Why Regeneron Pharmaceuticals Inc. (RGO) stock is a strong buy callCPI Data & Reliable Breakout Forecasts - newser.com
JW Therapeutics and Regeneron Expand Strategic Collaboration Agreement to Advance TCR-T Cell Therapy Development and Maximize Global Platform Potential - The Manila Times
Opko Health Inc.’s (OPK) ModeX Therapeutics Announces License and Collaboration Agreement With Regeneron Pharmaceuticals - Insider Monkey
Biopharma stocks regain ground in Q3 but still lag major indexes - BioWorld MedTech
Citigroup Issues Positive Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $708.00 at Royal Bank Of Canada - MarketBeat
Regeneron receives FDA CRL, delaying Eylea HD sBLA approval - Eyes On Eyecare
Wells Fargo & Company Issues Positive Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price - MarketBeat
Cantor Fitzgerald Boosts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $740.00 - MarketBeat
Regeneron (REGN) Margin Compression Reinforces Cautious Community Narratives Heading Into Earnings Season - Yahoo Finance
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $865.00 at Guggenheim - MarketBeat
Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.44%
0.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):